Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | CASP6 | P55212 | 1/20 | 0.35 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.33 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.33 |
| ▸ | RPS6KA5 | O75582 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14390103 | 0.79 | ALDH1A1 (0.42) | ALDH1A1L3MBTL1SMN1; SMN2KMT2AMAPT | |
| SCHEMBL15282441 | 0.79 | ALDH1A1 (0.42) | ALDH1A1L3MBTL1SMN1; SMN2KMT2AMAPT | |
| SCHEMBL8664351 | 0.79 | ALDH1A1 (0.42) | ALDH1A1L3MBTL1SMN1; SMN2KMT2AMAPT | |
| SCHEMBL23695123 | 0.79 | ALDH1A1 (0.42) | ALDH1A1L3MBTL1SMN1; SMN2KMT2AMAPT | |
| SCHEMBL1427749 | 0.78 | ALDH1A1 (0.41) | ALDH1A1L3MBTL1SMN1; SMN2KMT2AMAPT | |
| SCHEMBL1554936 | 0.76 | ALDH1A1 (0.40) | ALDH1A1L3MBTL1SMN1; SMN2KMT2AMAPT | |
| SCHEMBL24922312 | 0.75 | ALDH1A1 (0.39) | ALDH1A1L3MBTL1SMN1; SMN2KMT2AMAPT | |
| SCHEMBL15321296 | 0.75 | ALDH1A1 (0.42) | ALDH1A1L3MBTL1SMN1; SMN2KMT2AMAPT | |
| SCHEMBL1143136 | 0.71 | — | — | |
| SCHEMBL19250319 | 0.71 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7220753-B2 | 2,7-substituted octahydro-1H-pyrido[1,2-a]pyrazine derivatives as ligands for serotonin receptors | PFIZER INC. (US) | 2007-05-22 | — | — | US | disclosed |
| US-20040214830-A1 | 2,7-Substituted octahydro-1H-pyrido[1,2-a]pyrazine derivatives as ligands for serotonin receptors | DESAI KISHOR A | 2004-10-28 | — | — | US | disclosed |
| US-20030055061-A1 | 2,7-substituted octahydro-1H-pyrido[1,2-A]pyrazine derivatives as ligands for serotonin receptors | PFIZER INC. | 2003-03-20 | — | — | US | disclosed |
| US-20020132811-A1 | 2,7-substituted octahydro-1H-pyrido[1,2-A]pyrazine derivatives as ligands for serotonin receptors | DESAI KISHOR A (US) | 2002-09-19 | — | — | US | disclosed |
| EP-0783503-B1 | 2,7-SUBSTITUTED OCTAHYDRO-1H-PYRIDO[ 1,2-A]PYRAZINE DERIVATIVES | PFIZER (US) | 2001-11-28 | — | — | EP | disclosed |
| US-6231833-B1 | ADMINISTERING TO THE MAMMAL FOR TREATING SEROTONIN SYSTEM RELATED DISORDERS AN EFFECTIVE AMOUNT OF 2,7-SUBSTITUTED OCTAHYDRO-1H-PYRIDO(1,2-A)PYRAZINE DERIVATIVE AS LIGANDS FOR SEROTONIN RECEPTOR | PFIZER INC | 2001-05-15 | — | — | US | disclosed |
| EP-1074257-A1 | 2,7-Substituted octahydro-1H-pyrido (1,2-A)pyrazine derivatives as ligands for serotonin receptors | Pfizer Products Inc. (US) | 2001-02-07 | — | — | EP | disclosed |
| US-5852031-A | 2,7-substituted octahydro-1H-pyrido 1,2-a!pyrazine derivatives | PFIZER INC. (US) | 1998-12-22 | — | — | US | disclosed |
| EP-0783503-A1 | 2,7-SUBSTITUTED OCTAHYDRO-1H-PYRIDO 1,2-a]PYRAZINE DERIVATIVES | PFIZER INC. (US) | 1997-07-16 | — | — | EP | disclosed |
| WO-1996010571-A1 | 2,7-SUBSTITUTED OCTAHYDRO-1H-PYRIDO[1,2-a]PYRAZINE DERIVATIVES | PFIZER INC. (US) | 1996-04-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020132811-A1 | 2,7-substituted octahydro-1H-pyrido[1,2-A]pyrazine derivatives as ligands for serotonin receptors | HTR2C, HTR1A, HTR3A | ALDH1A1 688/4885L3MBTL1 4277/4885SMN1; SMN2 3394/4885 |
| US-20040214830-A1 | 2,7-Substituted octahydro-1H-pyrido[1,2-a]pyrazine derivatives as ligands for serotonin receptors | HTR2C, HTR1A, HTR3A | ALDH1A1 688/4885L3MBTL1 4277/4885SMN1; SMN2 3394/4885 |
| US-20030055061-A1 | 2,7-substituted octahydro-1H-pyrido[1,2-A]pyrazine derivatives as ligands for serotonin receptors | HTR2C, HTR1A, HTR3A | ALDH1A1 688/4885L3MBTL1 4277/4885SMN1; SMN2 3394/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.